CoChat

Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Open access
Luan, Sisi, Cheng, Wenke, Wang, Chenglong, Gong, Jianhong, Zhou, Jianbo · 2022 · Frontiers in Endocrinology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background: Diabetes is an independent risk factor for cognitive impairment. However, little is known about the neuroprotective effects of glucagon-like peptide 1 (GLP-1) analogs on type 2 diabetes mellitus (T2DM). Herein, we assessed the impact of GLP-1 analogs on the general cognitive functioning among patients with T2DM. Methods: Relevant studies were retrieved from PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases from their inception till June 30, 2022, without any language restrictions. For continuous variables, the mean and standard deviation (SD) were extracted. Considering the heterogeneity in general cognitive functioning assessments among the pooled studies, the standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs), were calculated. Results: Five studies including 7,732 individuals with T2DM were selected for the meta-analysis. The use of GLP-1 analogs exerted no significant effects on the general cognitive functioning in self-controlled studies (SMD 0.33, 95% CI -0.03 to 0.69). Subgroup analyses among the self-controlled studies based on age and history of cardio-cerebrovascular disease showed that GLP-1 analogs significantly improved the general cognitive functioning in T2DM patients younger than 65 years (SMD 0.69, 95% CI 0.31 to 1.08) or those without cardio-cerebrovascular diseases (SMD 0.69, 95% CI 0.31 to 1.08). Similarly, differences in the general cognitive functioning for GLP-1 analogs between treated and non-treated patients with T2DM were significant in subgroups with patients younger than 65 years (SMD 1.04, 95% CI 0.61 to 1.47) or those with no history of cardio-cerebrovascular diseases (SMD 1.04, 95% CI 0.61 to 1.47). Conclusion: Limited evidence suggests that the use of GLP-1 analogs exerts no significant effects on general cognitive functioning but may be beneficial for patients with T2DM younger than 65 years or those without a history of cardio-cerebrovascular diseases. Further prospective clinical studies with large sample sizes are needed to validate these findings. Systematic Review Registration: www.inplasy.com, identifier 202260015.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1047883

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of study selection for the meta-analysis.
Figure 1 Flow chart of study selection for the meta-analysis.CC BY · PubMed Central
Figure 2 Forest plots of random-effects meta-analysis (between-study variance estimator: DerSimonian and Laird (DL)) for the differences in cognitive function before and after treatment with GLP-1 analogs. Shown are the standardized mean differences (SMDs) together with their 95% confidence intervals (CIs) as effect measures.
Figure 2 Forest plots of random-effects meta-analysis (between-study variance estimator: DerSimonian and Laird (DL)) for the differences in cognitive function before and after treatment with GLP-1 analogs. Shown are the standardized mean differences (SMDs) together with their 95% confidence intervals (CIs) as effect measures.CC BY · PubMed Central
Figure 3 Forest plots of random-effects meta-analysis (between-study variance estimator: DerSimonian and Laird (DL)) for the differences in cognitive function between treated and non-treated groups with GLP-1 analogs. Shown are the SMDs together with their 95% CIs as effect measures.
Figure 3 Forest plots of random-effects meta-analysis (between-study variance estimator: DerSimonian and Laird (DL)) for the differences in cognitive function between treated and non-treated groups with GLP-1 analogs. Shown are the SMDs together with their 95% CIs as effect measures.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Wang, 2020, Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment, Int J Clin Exp Med, 13

Cited by

See all 25

Metadata

Authors
Luan, S., Cheng, W., Wang, C., Gong, J., & Zhou, J.
Affiliations
  • Beijing Tongren Hospital (CN)
  • Leipzig University (DE)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Zhou, Jianbo
Venue
Frontiers in Endocrinology
Published
2022-10-28
Volume
13
Pages
1047883-1047883
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4307704054
Cited by
25
References
33
Citations by year
2026: 4 · 2025: 13 · 2024: 4 · 2023: 4
FWCI
0.75
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Qucosa (Saxon State and University Library Dresden) (submittedVersion, cc-by)
Funders
National Natural Science Foundation of China (82270866, 82100828)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
glucagon-like peptide-1 analogues, type 2 diabetes, cognitive function, cognitive impairment, neuroprotection, cardio-cerebrovascular disease, age, self-controlled study, GLP-1 receptor agonists, older adults, young adults, standardized mean difference, meta-regression
MeSH terms
Cognition, Diabetes Mellitus, Type 2, Humans, Risk Factors, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2022.1047883
The paper
Luan, S., Cheng, W., Wang, C., Gong, J., & Zhou, J. (2022). Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1047883

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.